Experimental cell therapy tested on patients with untreatable autoimmune diseases
NCT ID NCT07236762
Summary
This is an early-stage safety study testing a single infusion of YTS109 cells in 18 adults with severe autoimmune diseases that have not responded to standard treatments. The main goal is to check for side effects and see how the body handles the cells. Researchers will also look for early signs that the treatment might help control diseases like lupus, Sjogren's syndrome, and related conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The third people's Hospital of Bengbu
RECRUITINGBengbu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.